The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Abstract Background Currently, the value of oral selective estrogen receptor degraders (SERDs) for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) after progression on ≥ 1 line of endocrine therapy (ET) remains controversial....

Full description

Bibliographic Details
Main Authors: Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, Chuangui Song
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Breast cancer
Advance
HR+/HER2-
Oral SERDs
Meta-analysis
Online Access:https://doi.org/10.1186/s12885-023-11722-4

Internet

https://doi.org/10.1186/s12885-023-11722-4

Similar Items